Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
Authors
Keywords
-
Journal
Lancet Microbe
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-01-25
DOI
10.1016/s2666-5247(21)00280-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas
- (2021) Xianwen Ren et al. CELL
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
- (2021) Jingxin Li et al. NATURE MEDICINE
- A novel coronavirus outbreak of global health concern
- (2020) Chen Wang et al. LANCET
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
- (2020) Mingfeng Liao et al. NATURE MEDICINE
- Rapid COVID-19 vaccine development
- (2020) Barney S. Graham SCIENCE
- A Thermostable mRNA Vaccine against COVID-19
- (2020) Na-Na Zhang et al. CELL
- A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
- (2020) Wanbo Tai et al. CELL RESEARCH
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
- (2020) Lakshmanane Premkumar et al. Science Immunology
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
- (2020) Takuya Sekine et al. CELL
- COVID-19 Makes B Cells Forget, but T Cells Remember
- (2020) Pablo F. Cañete et al. CELL
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
- (2020) Jinkai Zang et al. Cell Discovery
- Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
- (2020) Lauren B. Rodda et al. CELL
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial
- (2019) Fatma Doener et al. VACCINE
- mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
- (2019) Giulietta Maruggi et al. MOLECULAR THERAPY
- Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
- (2019) Sergio Linares-Fernández et al. TRENDS IN MOLECULAR MEDICINE
- Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection
- (2016) Oi-Wing Ng et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search